Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Rani Therapeutics Holdings (RANI – Research Report) and keeping the price target at $9.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mitchell Kapoor has given his Buy rating due to a combination of factors, primarily driven by the positive preclinical data from Rani Therapeutics Holdings. The company’s recent announcement highlighted the successful oral delivery of semaglutide using the RaniPill capsule, which showed comparable results to the subcutaneous version in terms of bioavailability, pharmacokinetics, and weight loss. This advancement represents a significant step forward in Rani’s obesity treatment platform, offering a once-weekly oral administration that could enhance patient adherence and overall treatment outcomes.
In addition, Rani is actively progressing with its RT-114 program, expected to enter Phase 1 trials soon, which further underpins the firm’s strategic growth in the obesity sector. Kapoor’s valuation analysis, using a risk-adjusted net present value approach, supports a 12-month price target of $9 per share. However, the report does caution about potential risks, including negative clinical trial outcomes and partnership uncertainties, which could impact future stock performance.
Kapoor covers the Healthcare sector, focusing on stocks such as Halozyme, Sarepta Therapeutics, and Rallybio. According to TipRanks, Kapoor has an average return of -15.1% and a 30.56% success rate on recommended stocks.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $8.00 price target.